Mitchell R. Smith, MD, PhD

Mitchell R. Smith, MD, PhD, discusses the patient population of the phase 2 ECOG-ACRIN E1411 trial in mantle cell lymphoma.

Mitchell R. Smith, MD, PhD, discusses the rationale for the phase 2 ECOG-ACRIN E1411 trial in mantle cell lymphoma.

Mitchell R. Smith, MD, PhD, discusses the results of the phase 2 ECOG-ACRIN E1411 trial in mantle cell lymphoma.

Mitchell R. Smith, MD, PhD, discusses the rationale behind the trial looking at the fixed duration of the ibrutinib and venetoclax combination in chronic lymphocytic leukemia.

Mitchell R. Smith, MD, PhD, division director, Cancer and Blood Disorders, and professor of medicine, GW Cancer Center, discusses the use of PI3K inhibitors in chronic lymphocytic leukemia (CLL).

Mitchell R. Smith, MD, PhD, discusses frontline treatment considerations in patients with chronic lymphocytic leukemia.

Mitchell R. Smith, MD, PhD, discusses the use of venetoclax versus ibrutinib in patients with chronic lymphocytic leukemia.

Mitchell R. Smith, MD, PhD, discusses the potential advantage of lenalidomide in chronic lymphocytic leukemia.

Mitchell R. Smith, MD, PhD, discusses two randomized phase III trials investigating the benefit of ibrutinib-based therapies in patients with chronic lymphocytic leukemia.

Mitchell R. Smith, MD, PhD, professor of medicine, George Washington University, associate center director for clinical investigations, Division of Hematology and Oncology, GW Cancer Center, discusses emerging therapeutic approaches in indolent lymphoma.